Art

J-GLOBAL ID：202102284114626850   Reference number：21A0137840

Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer

非小細胞肺癌患者におけるデュルバルマブ誘発性免疫関連肝炎

Author (11)： Nakamura Masakatsu (Department of Gastroenterology, Kanazawa Medical University, Japan) ,  Otsuka Toshimi (Department of Gastroenterology, Kanazawa Medical University, Japan) ,  Hayashi Ranji (Department of Gastroenterology, Kanazawa Medical University, Japan) ,  Horita Tomoe (Department of Gastroenterology, Kanazawa Medical University, Japan) ,  Ota Masafumi (Department of Gastroenterology, Kanazawa Medical University, Japan) ,  Sakurai Naoko (Department of Gastroenterology, Kanazawa Medical University, Japan) ,  Takano Hikaru (Department of Gastroenterology, Kanazawa Medical University, Japan) ,  Hayashi Tasuku (Department of Gastroenterology, Kanazawa Medical University, Japan) ,  Kumagai Motona (Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Japan) ,  Yamada Sohsuke (Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Japan) ,  Arisawa Tomiyasu (Department of Gastroenterology, Kanazawa Medical University, Japan)
Material： Internal Medicine (Web)  (Intern Med (Web))
Volume： 59  Issue： 21  Page： 2711-2717(J-STAGE)  Publication year： 2020 
JST Material Number： U0033A  ISSN： 1349-7235  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： carboplatin ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=21A0137840&from=J-GLOBAL&jstjournalNo=U0033A") }}

Author keywords (3)： immune-related hepatitis ,  durvalumab ,  non-small cell lung cancer

JST classification (4)： Clinical oncology in general  (GE03010Y) ,  Tumors(=neoplasms)of respiratory system  (GI04000G) ,  Digestive system diseases  (GH03000W) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Substance index (2)： Paclitaxel ,  Methylprednisolone

Reference (20)：

• 1. Guidelines for medical treatment of lung cancer 2019 edition Japan Lung Cancer Society.
• 2. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stageIII non-small-cell lung cancer. N Engl J Med 377: 1919-1929, 2017.
• 3. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379: 2342-2350, 2018.
• 4. Osta B. El, Hu F, Sadak R, et al. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol 119: 1-12, 2017.
• 5. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 366: 2517-2519, 2012.

Terms in the title (5)： 非小細胞肺癌 ,  患者 ,  デュルバルマブ ,  免疫 ,  肝炎